JP2010533181A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533181A5
JP2010533181A5 JP2010516053A JP2010516053A JP2010533181A5 JP 2010533181 A5 JP2010533181 A5 JP 2010533181A5 JP 2010516053 A JP2010516053 A JP 2010516053A JP 2010516053 A JP2010516053 A JP 2010516053A JP 2010533181 A5 JP2010533181 A5 JP 2010533181A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
tnfα
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010516053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/008458 external-priority patent/WO2009011782A2/en
Publication of JP2010533181A publication Critical patent/JP2010533181A/ja
Publication of JP2010533181A5 publication Critical patent/JP2010533181A5/ja
Withdrawn legal-status Critical Current

Links

JP2010516053A 2007-07-13 2008-07-10 ＴＮＦα阻害剤の肺投与のための方法及び組成物 Withdrawn JP2010533181A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95942607P 2007-07-13 2007-07-13
PCT/US2008/008458 WO2009011782A2 (en) 2007-07-13 2008-07-10 METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013220124A Division JP2014062095A (ja) 2007-07-13 2013-10-23 ＴＮＦα阻害剤の肺投与のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2010533181A JP2010533181A (ja) 2010-10-21
JP2010533181A5 true JP2010533181A5 (cg-RX-API-DMAC7.html) 2011-08-25

Family

ID=40260243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010516053A Withdrawn JP2010533181A (ja) 2007-07-13 2008-07-10 ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP2013220124A Pending JP2014062095A (ja) 2007-07-13 2013-10-23 ＴＮＦα阻害剤の肺投与のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013220124A Pending JP2014062095A (ja) 2007-07-13 2013-10-23 ＴＮＦα阻害剤の肺投与のための方法及び組成物

Country Status (7)

Country Link
US (1) US20090110679A1 (cg-RX-API-DMAC7.html)
EP (1) EP2173380A4 (cg-RX-API-DMAC7.html)
JP (2) JP2010533181A (cg-RX-API-DMAC7.html)
CN (1) CN101848733A (cg-RX-API-DMAC7.html)
CA (1) CA2693771A1 (cg-RX-API-DMAC7.html)
TW (1) TW200922618A (cg-RX-API-DMAC7.html)
WO (1) WO2009011782A2 (cg-RX-API-DMAC7.html)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
CA2493067A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
JP5198277B2 (ja) * 2005-11-01 2013-05-15 アボツト・バイオテクノロジー・リミテツド バイオマーカーを用いて強直性脊椎炎を診断するための方法及び組成物
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) * 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
TWI542374B (zh) 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
EP2089428B1 (en) * 2006-10-27 2013-11-20 AbbVie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
FR2909643B1 (fr) * 2006-12-11 2011-03-04 Valois Sas Dispositif de distribution de produit fluide
EP2165194A4 (en) * 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
MX2010001488A (es) 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
US20090271164A1 (en) * 2008-01-03 2009-10-29 Peng Joanna Z Predicting long-term efficacy of a compound in the treatment of psoriasis
RU2537139C2 (ru) 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
DK2303291T3 (da) * 2008-05-23 2013-05-27 Lauridsen Group Inc IgA og IgG til nedbringelse af lungebetændelse i et dyr
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
RU2524487C2 (ru) 2009-04-29 2014-07-27 Эббви Байотекнолоджи Лтд Автоматическое инъекционное устройство
CN104490767A (zh) * 2009-05-04 2015-04-08 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
WO2011075524A1 (en) 2009-12-15 2011-06-23 Abbott Biotechnology Ltd Improved firing button for automatic injection device
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
GB201005064D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
BR112012027900A2 (pt) 2010-04-30 2020-05-12 Alexion Pharmaceuticals, Inc. Anticorpos anti-c5a e métodos para usar os anticorpos
PL2575884T3 (pl) 2010-06-03 2018-12-31 Abbvie Biotechnology Ltd Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
AU2012209223B2 (en) 2011-01-24 2015-11-05 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CA2880011C (en) * 2012-07-24 2021-02-16 Mark William Surber Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
MX381503B (es) * 2013-05-23 2025-03-12 Aztherapies Inc Métodos para la liberación de cromolina.
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201701276SA (en) * 2014-08-26 2017-03-30 Kirin Amgen Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
RU2018141451A (ru) 2016-05-27 2020-06-29 Алексион Фармасьютикалс, Инк. Способы лечения рефрактерной генерализованной миастении
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
EP3652210A1 (en) 2017-07-14 2020-05-20 CytomX Therapeutics, Inc. Anti-cd166 antibodies and uses thereof
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Aspeya US Inc. Dry powder compositions with magnesium stearate
MX2020004284A (es) 2017-10-26 2020-10-28 Alexion Pharma Inc Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
SG11202009925PA (en) * 2018-03-08 2020-11-27 Applied Molecular Transport Inc Toxin-derived delivery constructs for oral delivery
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
KR20210084533A (ko) 2018-10-30 2021-07-07 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨증 (pnh)의 치료를 위한 항-c5 항체의 피하 투여량 및 투여
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
JP7386382B2 (ja) 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS
AU2021259628A1 (en) 2020-04-24 2023-01-05 Millennium Pharmaceuticals, Inc. Anti-CD19 antibodies and uses thereof
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN117425673A (zh) 2021-04-09 2024-01-19 武田药品工业株式会社 靶向补体因子d的抗体和其用途
EP4330284A2 (en) 2021-04-26 2024-03-06 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
WO2022232035A1 (en) 2021-04-26 2022-11-03 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
EP4419561A2 (en) 2021-10-20 2024-08-28 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
CN116763763B (zh) * 2022-12-05 2024-08-30 齐鲁制药有限公司 一种司美格鲁肽吸入喷雾剂及其制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6000A (en) * 1849-01-02 Abunah s
GB9015522D0 (en) * 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6427682B1 (en) * 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
US5826571A (en) * 1995-06-08 1998-10-27 Innovative Devices, Llc Device for use with metered dose inhalers (MDIS)
IL122494A (en) * 1995-06-21 2001-08-08 Asta Medica Ag A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
WO1998048837A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
ES2189269T3 (es) * 1997-12-03 2003-07-01 Britannia Pharmaceuticals Ltd Mejoras en medicamentos para el tratamiento del asma.
GB9827200D0 (en) * 1998-12-11 1999-02-03 Glaxo Group Ltd Dry powder inhaler
PT1159003E (pt) * 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
CA2369262A1 (en) * 1999-04-13 2000-10-19 Sudha Nagarajan Pulmonary administration of dry powder formulations for treating infertility
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10123749A1 (de) * 2001-05-16 2002-12-12 Inamed Gmbh Vorrichtung zum Verabreichen von Aerosolen
BR0206160A (pt) * 2001-05-25 2004-10-26 Abbott Gmbh & Co Kg Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
WO2003030974A1 (en) * 2001-10-08 2003-04-17 Eli Lilly And Company Portable medication inhalation kit
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
CA2479212A1 (en) * 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
CA2493067A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP5757495B2 (ja) * 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
JP5198277B2 (ja) * 2005-11-01 2013-05-15 アボツト・バイオテクノロジー・リミテツド バイオマーカーを用いて強直性脊椎炎を診断するための方法及び組成物
EP2738179A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
EP2666472A3 (en) * 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) * 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
TWI542374B (zh) * 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
MX345141B (es) * 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
EP2089428B1 (en) * 2006-10-27 2013-11-20 AbbVie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
EP2165194A4 (en) * 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
WO2008154543A2 (en) * 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
MX2010001488A (es) * 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
CN101802005B (zh) * 2007-08-28 2015-09-16 艾伯维生物技术有限公司 包括关于阿达木单抗的结合蛋白质的组合物和方法
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US8883146B2 (en) * 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20090271164A1 (en) * 2008-01-03 2009-10-29 Peng Joanna Z Predicting long-term efficacy of a compound in the treatment of psoriasis
NZ586576A (en) * 2008-01-15 2012-08-31 Abbott Lab Improved mammalian expression vectors and uses thereof
RU2537139C2 (ru) * 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
EP2271671A2 (en) * 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
CN104490767A (zh) * 2009-05-04 2015-04-08 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
US20120014956A1 (en) * 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
PL2575884T3 (pl) * 2010-06-03 2018-12-31 Abbvie Biotechnology Ltd Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)

Similar Documents

Publication Publication Date Title
JP2010533181A5 (cg-RX-API-DMAC7.html)
JP6200806B2 (ja) 二重特異的融合タンパク質
JP5914356B2 (ja) インターフェロンアナログ
CN101711256B (zh) 针对il-25的抗体
JP2016512554A5 (cg-RX-API-DMAC7.html)
EP4198055A1 (en) Antibody of il-11 and use thereof
Menzella et al. Tailored therapy for severe asthma
JP2005523946A5 (cg-RX-API-DMAC7.html)
JP2013507131A5 (cg-RX-API-DMAC7.html)
CN102482352B (zh) 抗il-17br的抗体
JP2002539072A5 (cg-RX-API-DMAC7.html)
CN101848733A (zh) 用于肺部给予TNFα抑制剂的方法和组合物
JP2008521870A5 (cg-RX-API-DMAC7.html)
JP6469012B2 (ja) インターロイキン−６に対する抗体およびその使用
JP2016537340A5 (cg-RX-API-DMAC7.html)
CN102307896A (zh) 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
AU2008334605A1 (en) Polypeptides, antibody variable domains & antagonists
WO2021042694A1 (zh) 抗vegf单域抗体及其应用
KR20170093120A (ko) Rsv 감염의 치료 방법
JP2004534513A5 (cg-RX-API-DMAC7.html)
RU2007124730A (ru) Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1
CN103030687B (zh) 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
US12012456B2 (en) Anti-interleukin-4 receptor (IL-4R) single-domain antibody, encoding polynucleotide and methods of making and using the antibody for IL-4R detection and disease treatment
JP2017528454A5 (cg-RX-API-DMAC7.html)
AU2022303437A1 (en) Anti-trop2 single-domain antibody and use thereof